LONDON, UK / ACCESSWIRE / January 25, 2018 /Active-Investors.com has just released a free earnings report on Johnson & Johnson (NYSE: JNJ). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=JNJ. The Company posted its fourth quarter fiscal 2017 (Q4 FY17) and full fiscal 2017 (FY17) financial results on January 23, 2018. The New Brunswick, New Jersey-based Company's quarterly sales grew 11.5% y-o-y, whereas adjusted diluted EPS increased 10.1% y-o-y in Q4 FY17. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Johnson & Johnson most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
Johnson & Johnson reported sales of $20.20 billion in Q4 FY17, which came in above the $18.11 billion recorded in the prior year's same quarter. Meanwhile, the market had expected sales of $20.22 billion. During the quarter, operation sales growth attributed 9.4% to quarterly sales growth, whereas the positive currency impact on the Company's quarterly sales growth was 2.1%.
In Q4 FY17, Johnson & Johnson reported a net loss of $10.71 billion, or $3.99 loss per diluted share, compared to net earnings of $3.81 billion, or $1.38 per diluted share, in Q4 FY16. The Company's adjusted net income came in at $4.78 billion, or $1.74 per diluted share, in Q4 FY17 versus $4.36 billion, or $1.58 per diluted share, in Q4 FY16. For the reported quarter, analysts were expecting the Company to report an adjusted net income of $1.72 per diluted share.
During FY17, the Company reported sales of $76.45 billion, up 6.3% from $71.89 billion in FY16. Johnson & Johnson's net earnings came in at $1.30 billion, or $0.47 per diluted share, for FY17 compared to $16.54 billion, or $5.93 per diluted share, recorded in FY16. Additionally, the Company's adjusted net income was $20.04 billion, or $7.30 per diluted share, during FY17, up from $18.76 billion, or $6.73 per diluted share, in the year ago comparable period.
The maker of biotech drugs and Band-Aids recorded cost of products sold of $7.24 billion in Q4 FY17, up 30.9% from $5.53 billion in Q4 FY16. Selling, marketing, and administrative expenses grew 13.5% to $6.03 billion y-o-y in Q4 FY17. Research and development (R&D) expenses increased to $3.64 billion in Q4 FY17 from $2.64 billion in the last year. Furthermore, the Company's earnings before provision for taxes on income came in at $2.56 billion, or 12.7% of quarterly sales, for Q4 FY17 compared to $4.32 billion, or 23.9% of quarterly sales.
In Q4 FY17, the Company's consumer segment reported a 3.1% y-o-y growth to stand at $3.54 billion from $3.43 billion in Q4 FY16. Johnson & Johnson's pharmaceutical sales were up by 17.6% to $9.68 billion in Q4 FY17 from $8.23 billion in Q4 FY16. In the reported quarter, medical devices sales improved 8.3% to $6.97 billion from $6.44 billion in year ago corresponding period.
The Company's US operations recorded a 9.8% sales growth to $10.47 billion in Q4 FY17 from $9.54 billion in the last year's same quarter. The International operations witnessed a 13.5% sales growth to $9.73 billion in Q4 FY17 from $8.57 billion in Q4 FY16.
In a separate press release on January 02, 2018, Johnson & Johnson's Board of Directors announced a cash dividend for Q1 FY18 of $0.84 per share on the Company's common stock. The dividend is payable on March 13, 2018, to shareholders of record at the close of business on February 27, 2018.
In its guidance for the full year FY18, the Company projects sales to grow in the range of 3.5% to 4.5%, and expects it to be between $79.1 billion and $79.9 billion. Adjusted EPS for the upcoming year is anticipated to rise in the band of 6.8% to 9.6%, and is forecasted to be between $7.80 and $8.00.
Stock Performance Snapshot
January 24, 2018 - At Wednesday's closing bell, Johnson & Johnson's stock marginally rose 0.17%, ending the trading session at $142.07.
Volume traded for the day: 12.46 million shares, which was above the 3-month average volume of 5.73 million shares.
Stock performance in the last month – up 0.72%; previous six-month period – up 7.73%; past twelve-month period – up 27.12%; and year-to-date – up 1.68%
After yesterday's close, Johnson & Johnson's market cap was at $380.53 billion.
Price to Earnings (P/E) ratio was at 24.69.
The stock has a dividend yield of 2.37%.
The stock is part of the Healthcare sector, categorized under the Drug Manufacturers - Major industry. This sector was up 0.3% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2018 Accesswire. All Rights Reserved.